China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Google Secures Pentagon AI Deal for Classified Projects 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
CAMBRIDGE, Mass., Feb. 03, 2016 -- SAGE Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will present at the 2016 Leerink Global Healthcare Conference at 3:55 PM ET on Wednesday, February 10, 2016, in New York City.
A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. Sage is developing its next generation modulators, including SAGE-217, SAGE-689 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.
Investor Contact: Paul Cox, Sage Therapeutics [email protected] 617-299-8377 Media Contact: Maureen L. Suda, Suda Communications LLC [email protected] 585-387-9248
